Gemcitabine + Cisplatin (for recurrent/metastatic NPC)
Treatment for Nasopharynx Cancer
Typical Dosage: Gemcitabine 1000 mg/m2 on day 1 and 8, Cisplatin 80 mg/m2 on day 1, every 3 weeks.
Effectiveness
75%
Safety Score
25%
Clinical Trials
21
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Gemcitabine 1000 mg/m2 on day 1 and 8, Cisplatin 80 mg/m2 on day 1, every 3 weeks.
Time to Effect
Within weeks of starting cycles
Treatment Duration
3-6 cycles
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$15,000
Side Effect Mgmt:$15,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$64,286
Cost per Remission
$450,000
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Gemcitabine + Cisplatin (for recurrent/metastatic NPC) Outcomes
for Nasopharynx Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Remission Rate
+10%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia)
+70%
Nausea/Vomiting
+60%
Fatigue
+70%
Nephrotoxicity
+25%
Ototoxicity
+15%
Peripheral neuropathy
+15%
Sources:
Active Clinical Trials
8 active trials recruiting for Gemcitabine + Cisplatin (for recurrent/metastatic NPC) in Nasopharynx Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
NCT07325539RECRUITINGPHASE2
55 participants
INTERVENTIONAL
Guangzhou, China +1 more
Started: Jan 12, 2026
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06457503RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Little Rock, United States +12 more
Started: Nov 1, 2024
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05294172ACTIVE NOT RECRUITINGPHASE3
295 participants
INTERVENTIONAL
Beijing, China
Started: Jun 7, 2022
tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
NCT05517135RECRUITING
1K participants
OBSERVATIONAL
Singapore, Singapore
Started: Nov 17, 2022
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
NCT06241599RECRUITINGPHASE2, PHASE3
300 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 1, 2024
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07138989NOT YET RECRUITINGPHASE2
10 participants
INTERVENTIONAL
Guangzhou, China
Started: Aug 19, 2025
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
NCT06323239RECRUITINGPHASE2
148 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 15, 2024
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
NCT06802835RECRUITINGPHASE1, PHASE2
148 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 9, 2025
Completed Clinical Trials
5 completed trials for Gemcitabine + Cisplatin (for recurrent/metastatic NPC) in Nasopharynx Cancer
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
NCT03121716COMPLETEDPHASE1
23 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 26, 2017
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
NCT03924986COMPLETEDPHASE3
263 participants
INTERVENTIONAL
Hefei, China +36 more
Started: Mar 27, 2019
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
NCT01528618COMPLETEDPHASE3
362 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 21, 2012
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
NCT02759250COMPLETEDPHASE1
11 participants
INTERVENTIONAL
Ghent, Belgium
Started: Feb 1, 2015
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
NCT00603915COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Toronto, Canada
Started: Jun 1, 2006
Showing 20 of 23 total trials